Li Guangling, Yang Jing, Zhang Demei, Wang Xiaomei, Han Jingjing, Guo Xueya
Department of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Department of Pathology, Gansu Provincial Hospital, Lanzhou, China.
Front Cardiovasc Med. 2022 Jul 25;9:889706. doi: 10.3389/fcvm.2022.889706. eCollection 2022.
With the aging population and the increasing incidence of basic illnesses such as hypertension and diabetes (DM), the incidence of atrial fibrillation (AF) has increased significantly. AF is the most common arrhythmia in clinical practice, which can cause heart failure (HF) and ischemic stroke (IS), increasing disability and mortality. Current studies point out that myocardial fibrosis (MF) is one of the most critical substrates for the occurrence and maintenance of AF. Although myocardial biopsy is the gold standard for evaluating MF, it is rarely used in clinical practice because it is an invasive procedure. In addition, serological indicators and imaging methods have also been used to evaluate MF. Nevertheless, the accuracy of serological markers in evaluating MF is controversial. This review focuses on the pathogenesis of MF, serological evaluation, imaging evaluation, and anti-fibrosis treatment to discuss the existing problems and provide new ideas for MF and AF evaluation and treatment.
随着人口老龄化以及高血压和糖尿病（DM）等基础疾病发病率的上升，心房颤动（AF）的发病率显著增加。AF是临床实践中最常见的心律失常，可导致心力衰竭（HF）和缺血性卒中（IS），增加残疾率和死亡率。目前的研究指出，心肌纤维化（MF）是AF发生和维持的最关键基质之一。虽然心肌活检是评估MF的金标准，但由于其为侵入性操作，在临床实践中很少使用。此外，血清学指标和影像学方法也已用于评估MF。然而，血清学标志物评估MF的准确性存在争议。本综述聚焦于MF的发病机制、血清学评估、影像学评估及抗纤维化治疗，以探讨现存问题，并为MF和AF的评估与治疗提供新思路。
